

## **Meaningful involvement of Indonesian Drugs user Network in respond and availability HCV treatment access in Indonesia**

Andika Prayudi Wibaskakra<sup>1</sup>, Edo Agustian, Andika Prayudi Wibaskara<sup>1</sup>, Caroline Thomas<sup>1</sup>, Claudius Mone dan Andika Prayudi W<sup>1</sup>  
<sup>1</sup>PKNI (Indonesian Drugs User Network)

### **Background:**

Since 2011 HCV Advocacy with involvement Drugs user Community in Indonesia to push Government give attention on HCV<sup>1</sup>. Existence begin to be recognized and involved in strategic position<sup>2</sup>. Early 2016 MoH start establish sub directorate of Hepatitis. Prevalence of HCV 1.01%<sup>3</sup> and results of study of Peer Driven Intervention is involved 326 respondents in Jakarta, found 89.2% mono HCV infection, 52.3% co-infection with HIV-HCV, 53.4% , 88.1% had never been treated and 73.3% in Methadone therapy<sup>4</sup>. Indonesia needs a good HCV treatment availability and MoH provides 6000 DAA treatment programs<sup>5</sup> 13.

### **Methods:**

Publication of articles and implementation studies related HCV<sup>6</sup>. Build Partnership on HCV advocacy such with sub directorate of Hepatitis<sup>7</sup> and facilitated Gilead and MoH meetings related to Sovaldi prices. Various approaches in strategic positions continue processed, conduct National Consultation Meeting on HCV<sup>8</sup>, encouraging Indonesian FDA about DAA,s registration DAA process<sup>9</sup>, involved in procurement plan and distribution of DAA programs and coordination process<sup>10</sup>, entering HCV as an indicator of the achievement Indonesia HIV Intervention and involved on series of raising awareness activities.

### **Result:**

Done HCV related studie<sup>4</sup> and release of DAA drugs licenses approved and some registration processed. Decided Sovaldi 400 US Dollar. Involved in develop drafting of MoH regulation No 537, 2015 and guidance of HCV<sup>10</sup>. MoH, start program 6000 DAA treatment<sup>7</sup>. Involved of MoH expert committee of hepatitis meeting. Inclusion of daclatasvir in MoH budget plan 2018. Expert coalition allow internist<sup>11</sup> for DAA treatment implementation and trained 80 medical officers from 6 Provinces. Trained 60 HCV Peer Educators<sup>16</sup> and put HCV as indicator GF intervention achivement. Involved 163 drug users through HCV public discussion in 6 Provinces<sup>17</sup> and done 2 National Consultation Meeting on HCV<sup>19</sup>.

### **Conclusion:ba**

Meaningful involvement of Drugs user Community on HCV advocacy is made a real impact. Strategic partnerships are an important part of the success of HCV advocacy. This existence and process should be maintained and ensured involve in ensuring role of community and needs are accommodated in HCV respond in Indonesia. Hopefully thats efforts can support the Government, regarding Indonesia role in achieving the Global Target of HCV elimination by 2030.